Asset
OBECABTAGENE AUTOLEUCEL
Autolus Therapeutics plc American Depositary Share
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04404660 | phase1_2 | active_not_recruiting | 2020-06-03 | 2029-06-30 | Autolus Limited | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
| NCT06173518 | phase1 | recruiting | 2023-11-16 | 2027-11-01 | Autolus Limited | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) |
| NCT06333483 | phase1 | active_not_recruiting | 2024-02-02 | 2027-09-01 | Autolus Limited | Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus |
| NCT07139743 | phase1 | recruiting | 2025-08-04 | 2029-08-15 | Autolus Limited | Obe-cel in Refractory Progressive Forms of Multiple Sclerosis |
| NCT07053800 | phase2 | recruiting | 2026-01-16 | 2028-08-01 | Autolus Limited | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125813 | BLA | Autolus, Inc. |
Marketed products (1)
- Aucatzyl